Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2009

Open Access 01-12-2009 | Research article

LRP1 shedding in human brain: roles of ADAM10 and ADAM17

Authors: Qiang Liu, Juan Zhang, Hien Tran, Marcel M Verbeek, Karina Reiss, Steven Estus, Guojun Bu

Published in: Molecular Neurodegeneration | Issue 1/2009

Login to get access

Abstract

Background

The low-density lipoprotein receptor-related protein 1 (LRP1) plays critical roles in lipid metabolism, cell survival, and the clearance of amyloid-β (Aβ) peptide. Functional soluble LRP1 (sLRP1) has been detected in circulating human placenta; however, whether sLRP1 is also present in the central nervous system is unclear.

Results

Here we show that abundant sLRP1 capable of binding its ligands is present in human brain tissue and cerebral spinal fluid (CSF). Interestingly, the levels of sLRP1 in CSF are significantly increased in older individuals, suggesting that either LRP1 shedding is increased or sLRP1 clearance is decreased during aging. To examine potential effects of pathological ligands on LRP1 shedding, we treated MEF cells with Aβ peptide and found that LRP1 shedding was increased. ADAM10 and ADAM17 are key members of the ADAM family that process membrane-associated proteins including amyloid precursor protein and Notch. We found that LRP1 shedding was significantly decreased in MEF cells lacking ADAM10 and/or ADAM17. Furthermore, forced expression of ADAM10 increased LRP1 shedding, which was inhibited by ADAM-specific inhibitor TIMP-3.

Conclusion

Our results demonstrate that LRP1 is shed by ADAM10 and ADAM17 and functional sLRP1 is abundantly present in human brain and CSF. Dysregulated LRP1 shedding during aging could alter its function and may contribute to the pathogenesis of AD.
Appendix
Available only for authorised users
Literature
1.
Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994.CrossRefPubMed
2.
Selkoe D, Kopan R: Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003, 26: 565-597. 10.1146/annurev.neuro.26.041002.131334.CrossRefPubMed
3.
4.
Herz J, Bock HH: Lipoprotein receptors in the nervous system. Annu Rev Biochem. 2002, 71: 405-434. 10.1146/annurev.biochem.71.110601.135342.CrossRefPubMed
5.
Herz J, Chen Y: Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006, 7: 850-859. 10.1038/nrn2009.CrossRefPubMed
6.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993, 261: 921-923. 10.1126/science.8346443.CrossRefPubMed
7.
Rosenberg RN: The molecular and genetic basis of AD: the end of the beginning. Neurology. 2000, 54: 2045-2054.CrossRefPubMed
8.
Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK: LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008, 88: 887-918. 10.1152/physrev.00033.2007.PubMedCentralCrossRefPubMed
9.
Lutz C, Nimpf J, Jenny M, Boecklinger K, Enzinger C, Utermann G, Baier-Bitterlich G, Baier G: Evidence of functional modulation of the MEKK/JNK/cJun signaling cascade by the low density lipoprotein receptor-related protein (LRP). J Biol Chem. 2002, 277: 43143-43151. 10.1074/jbc.M204426200.CrossRefPubMed
10.
Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH: Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest. 2000, 106: 1159-1166. 10.1172/JCI11013.PubMedCentralCrossRefPubMed
11.
Herz J, Kowal RC, Goldstein JL, Brown MS: Proteolytic processing of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. EMBO J. 1990, 9: 1769-1776.PubMedCentralPubMed
12.
Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, Owensby DA: Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem. 1997, 272: 23946-23951. 10.1074/jbc.272.38.23946.CrossRefPubMed
13.
Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lübke T, Lena Illert A, von Figura K, Saftig P: The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet. 2002, 11: 2615-2624. 10.1093/hmg/11.21.2615.CrossRefPubMed
14.
Bu G, Geuze HJ, Strous GJ, Schwartz AL: 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J. 1995, 14: 2269-2280.PubMedCentralPubMed
15.
Li Y, Chen J, Lu W, McCormick LM, Wang J, Bu G: Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding. J Cell Sci. 2005, 118: 5305-5314. 10.1242/jcs.02651.CrossRefPubMed
16.
Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, Batra SK: Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol. 2003, 23: 1365-1371.PubMed
17.
Obermoeller-McCormick LM, Li Y, Osaka H, FitzGerald DJ, Schwartz AL, Bu G: Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci. 2001, 114: 899-908.PubMed
18.
Rebeck GW, Reiter JS, Strickland DK, Hyman BT: Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993, 11: 575-580. 10.1016/0896-6273(93)90070-8.CrossRefPubMed
19.
Deuss M, Reiss K, Hartmann D: Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res. 2008, 5: 187-201. 10.2174/156720508783954686.CrossRefPubMed
20.
Hoe HS, Cooper MJ, Burns MP, Lewis PA, Brug van der M, Chakraborty G, Cartagena CM, Pak DT, Cookson MR, Rebeck GW: The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J Neurosci. 2007, 27: 10895-10905. 10.1523/JNEUROSCI.3135-07.2007.CrossRefPubMed
21.
von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT: The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005, 280: 17777-17785. 10.1074/jbc.M414248200.CrossRefPubMed
22.
Bu G, Maksymovitch EA, Schwartz AL: Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells. J Biol Chem. 1993, 268: 13002-13009.PubMed
23.
Marschang P, Brich J, Weeber EJ, Sweatt JD, Shelton JM, Richardson JA, Hammer RE, Herz J: Normal development and fertility of knockout mice lacking the tumor suppressor gene LRP1b suggest functional compensation by LRP1. Mol Cell Biol. 2004, 24: 3782-3793. 10.1128/MCB.24.9.3782-3793.2004.PubMedCentralCrossRefPubMed
Metadata
Title
LRP1 shedding in human brain: roles of ADAM10 and ADAM17
Authors
Qiang Liu
Juan Zhang
Hien Tran
Marcel M Verbeek
Karina Reiss
Steven Estus
Guojun Bu
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2009
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-4-17

Other articles of this Issue 1/2009

Molecular Neurodegeneration 1/2009 Go to the issue

Research article

GSK-3β phosphorylation of functionally distinct tau isoforms has differential, but mild effects

Short report

Insulin-degrading enzyme is exported via an unconventional protein secretion pathway

Review

Alzheimer's disease: synaptic dysfunction and Aβ

Research article

Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy

Research article

Effects of chronic low dose rotenone treatment on human microglial cells

Research article

An exo-cell assay for examining real-time γ-secretase activity and inhibition